Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02968095 · ClinicalTrials.gov registry record · NA

Text Message Support to Prevent Smoking Relapse

A NA study of Tobacco Use Disorder, sponsored by Miami University.

Completed
Registry status
NA
Development phase
58
Enrollment target
1
Study location

NCT02968095 is a NA study of Tobacco Use Disorder that has completed, run by Miami University. The registered enrollment target is 58 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02968095, a NA study of Tobacco Use Disorder, has completed, sponsored by Miami University.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test a text message intervention for people who are beginning an attempt to quit smoking. The intervention seeks to teach people to think about their cravings to smoke in more helpful ways. The investigators expect that participants receiving the text message craving program will be less likely to begin smoking again compared to participants in a control condition.

Conditions Studied

Interventions

  • BEHAVIORAL Text Message Craving Program
  • BEHAVIORAL Self-Help Manual Plus Control Texts

Study Locations (1)

Ohio

  • Miami University - Oxford

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2018-08-07
Est. Completion 2019-08-23
Phase NA

Sponsor

Miami University

6 total trials

What the Registry Record Tells You About NCT02968095

The ClinicalTrials.gov registry entry for NCT02968095 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (76% lower). The listed sponsor is Miami University, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Text Message Craving Program is the first listed.

NCT02968095 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02968095 about?

NCT02968095 is a clinical study titled "Text Message Support to Prevent Smoking Relapse". The purpose of this research is to test a text message intervention for people who are beginning an attempt to quit smoking. The intervention seeks to teach people to think about their cravings to smoke in more helpful ways. The investigators expect that participants receiving the text message cravi...

What is the current status of trial NCT02968095?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2018-08-07. Estimated completion is 2019-08-23.

What conditions does trial NCT02968095 study?

This clinical trial studies the following conditions: Tobacco Use Disorder.

What interventions are being tested in trial NCT02968095?

The interventions under investigation include: Text Message Craving Program (BEHAVIORAL), Self-Help Manual Plus Control Texts (BEHAVIORAL).

Who is sponsoring clinical trial NCT02968095?

This trial is sponsored by Miami University, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02968095 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.